Table 4.
Factors associated with the kinetics of anti-SARS-CoV-2 (N) and (S) antibodies for COVID-19 convalescent patients during 15 months of follow-up.
| Factors | Anti-SARS-CoV-2 (N) | Anti-SARS-CoV-2 (S) | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibodies peak | Antibodies decay | Antibodies peak | Antibodies decay | |||||
| P value | 95% CI | P value | 95% CI | P value | 95% CI | P value | 95% CI | |
| Age, > 48 years | < 0.001 |
(− 0.85; − 0.34) |
0.007 |
(0.25; 1.63) |
< 0.001 |
(− 55.01; − 23.38) |
< 0.001 |
(67.96; 132.56) |
| Rh, (+) | 0.001 |
(0.21; 0.78) |
< 0.001 |
(− 2.53; − 1.09) |
< 0.001 |
(20.65; 52.32) |
0.002 |
(− 96.75; − 22.48) |
| Gender, female | 0.662 |
(− 0.21; 0.33) |
0.001 |
(0.47; 1.82) |
< 0.001 |
(14.47; 45.60) |
< 0.001 |
(103.99; 174.58) |
| Severity, severe/moderate | 0.558 |
(− 0.33; 0.18) |
0.213 |
(− 0.24; 1.06) |
0.473 |
(− 9.79; 21.083) |
< 0.001 |
(− 140.23; − 75.65) |